Vancouver, British Columbia
(FSCwire) - EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF)
(the “Company”) announces that it has signed an agreement to retain
Haywood Securities Inc. (“Haywood”) for a term of one year for
business and financial advisory, in addition to due diligence
consulting services.
Management believes that our main
digital healthcare company, the divestiture of the C&C
subsidiary and other subsidiaries will benefit greatly from
Haywood’s involvement. Haywood has recently participated in
multiple bought deal financings, and as a broker/dealer has listed
or up-listed companies in numerous sectors. Management looks
forward to working with the team at Haywood to develop the business
opportunities that are continually presented to the Company.
Contact: Ron Ozols, Director
EVITRADE Health Systems
Corporation
(formerly Auxellence Health
Corporation)
Twitter: @evitradehealth or
https://twitter.com/evitradehealth
Email: info@auxellence.com
Website: http://www.auxellence.com
CSE Micro-site:
http://thecse.com/en/listings/technology/evitrade-health-systems-corp
US OTC Markets:
http://www.otcmarkets.com/stock/AXHLF/news
About Haywood Securities
Inc.
Founded in 1981, Haywood is a
100 per cent employee-owned investment dealer with more than 275
employees in its Canadian offices in Vancouver, Calgary and
Toronto. Haywood Securities Inc. is a member of the Toronto Stock
Exchange, the TSX Venture Exchange, the Montreal Exchange (MEX),
the Canadian National Stock Exchange (CNSX), the Canadian Investor
Protection Fund (CIPF), and the Investment Industry Regulatory
Organization of Canada (IIROC). In addition, Haywood Securities
(USA) Inc., a wholly owned subsidiary, is a broker-dealer
registered to transact securities business in the United States and
is a member of the Financial Industry Regulatory Authority
(FINRA).
About EVITRADE Health
(CSE: EVA, OTCQB: AXHLF)
EVITRADE (formerly Auxellence
Health Corp.), was founded in 2013 to provide online “digital
healthcare” services for resolving common health problems. The
current markets are weight-loss, high blood pressure, high blood
glucose and heart arrhythmia.
Disclaimers – Forward Looking Statements
